On the Russian retail pharmaceutical market, 18.5 million packs of gastroprokinetic and antiemetic medicines were sold over the first eleven months of 2025, which is 5.1% higher than in the same period of 2024. From January to November 2025, Russian consumers spent RUB 11.3 billion on medicines in this category (at retail prices, including VAT), with the value of sales increasing by 17.1% year on year. It should be noted that total spending on these products has been rising every year, alongside growth in physical consumption. For the full year 2024, retail sales amounted to 19.5 million packs of such medicines (+8% versus 2023), with total spending reaching RUB 10.7 billion (+21.1%).

According to data from the RNC Pharma database Audit of Retail Sales of Medicines in Russia (total sell out), the core volume of sales in this category is generated by gastroprokinetics used in the treatment of functional gastrointestinal disorders. These include medicines with the active substances trimebutine, itopride, domperidone, and others. During the reporting period, products with the INN trimebutine accounted for nearly half of physical demand and 62% of the value of sales across the analyzed groups. At the same time, more than 18% of physical volume was attributable to medicines containing metoclopramide, while their share in total spending did not exceed 3.4% of category sales.

Domestic manufacturers dominate among producers of medicines used for functional gastrointestinal disorders, largely due to generic products. Russian-made medicines in this category account for almost 72% of physical consumption and around 77% of value sales. The top two positions in the brand ranking are occupied by domestically produced trimebutine-based products. Trimedat by Valenta has retained leadership in the group for several years, holding a 37.6% share of value sales, while its sales growth versus January–November 2024 reached +23% in ruble terms. Neobutin by Binnopharm remains in second place with a 22% share; spending on this product increased by 20% over the reporting period. Third place was taken by Ganaton (itopride) by Abbott, with an 8.1% share and growth of +19% in value terms. At the same time, Motilium by Johnson & Johnson fell to fourth position, as its sales declined by 4% year on year in rubles.

The highest growth within the Top 10 was recorded for unbranded itopride products, which are represented in retail by six different manufacturers: over the year, their combined sales increased by 55% in value terms and by 43% in packs. A comparable trend was observed for the gastrointestinal motility stimulant Dispevikt (INN acotiamide) by Dr. Reddy’s, whose sales versus January–November 2024 increased by 56% both in value and in physical terms.

Table. Top 10 brands of gastroprokinetic and antiemetic medicines (EphMRA groups A03F and A04A) by value sales on the Russian retail pharmaceutical market (including the online channel), January–November 2025